Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial
Interim data remains on track for summer 2026 and partnering discussions continue to advance with multiple companies
Highlights
· First patient dosed in the POLB 001 TOPICAL clinical trial
· Second site, University College London Hospital, activated with patient recruitment underway
· Additional clinical sites expected to open imminently, supporting continued patient recruitment
13 July 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, today announces that the first patient has been dosed in the POLB 001 TOPICAL clinical trial.
